NCT05982873Available不适用
Expanded Access to Telisotuzumab Adizutecan
AbbVie0 个研究点开始时间: 2023年8月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
- 发起方
研究概览
简要总结
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to telisotuzumab adizutecan prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Exclusion Criteria:
- •There are other suitable treatment options.
- •The participant qualifies for ongoing clinical trials.
排除标准
- 未提供
研究者
相似试验
No Longer Available
不适用
Expanded Access to ABT-414Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) DiagnosisNCT03123952AbbVie
No Longer Available
不适用
Expanded Access to ABBV-787Acute Myeloid LeukemiaNCT06439966AbbVie
Available
不适用
Expanded Access to ABBV-CLS-484Advanced Solid Tumor CancerNCT06188975Calico Life Sciences LLC
No Longer Available
不适用
Expanded Access to ABBV-8E12Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)NCT03744546AbbVie
No Longer Available
不适用
Expanded Access to VeliparibSolid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically SoundTriple Negative Breast Cancer (TNBC)High Grade Serous Ovarian CancerPatients Requiring Veliparib Suspension FormulationNCT03123211AbbVie